blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3630102

EP3630102 - FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.06.2025
Database last updated on 24.03.2026
FormerThe patent has been granted
Status updated on  12.07.2024
FormerGrant of patent is intended
Status updated on  07.05.2024
FormerExamination is in progress
Status updated on  29.04.2024
FormerGrant of patent is intended
Status updated on  04.01.2024
FormerExamination is in progress
Status updated on  10.02.2023
FormerRequest for examination was made
Status updated on  06.03.2020
FormerThe international publication has been made
Status updated on  01.12.2018
Most recent event   Tooltip06.02.2026Lapse of the patent in a contracting state
New state(s): MC		published on 11.03.2026  [2026/11]
Applicant(s)For all designated states
Glytech LLC.
100 Danforth Avenue
Dobbs Ferry, NY 10522 / US
[2024/20]
Former [2020/15]For all designated states
Glytech LLC.
800 Park Avenue Suite 1803
Ft. Lee, New Jersey 07024 / US
Inventor(s)01 / JAVITT, Daniel C.
34 Yehoshua Bin Nun Street
9318711 Jerusalem / IL
 [2020/15]
Representative(s)Schulz Junghans Patentanwälte PartGmbB
Großbeerenstraße 71
10963 Berlin / DE
[2020/15]
Application number, filing date18805411.824.05.2018
[2020/15]
WO2018IL50567
Priority number, dateUS201762510801P25.05.2017         Original published format: US 201762510801 P
US201762518020P12.06.2017         Original published format: US 201762518020 P
[2020/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018216018
Date:29.11.2018
Language:EN
[2018/48]
Type: A1 Application with search report 
No.:EP3630102
Date:08.04.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 29.11.2018 takes the place of the publication of the European patent application.
[2020/15]
Type: B1 Patent specification 
No.:EP3630102
Date:14.08.2024
Language:EN
[2024/33]
Search report(s)International search report - published on:IL29.11.2018
(Supplementary) European search report - dispatched on:EP15.03.2021
ClassificationIPC:A61K31/42, A61K31/4545, A61K31/497, A61K31/554, A61P25/24, A61K31/405, A61K9/00, A61K31/135, A61K31/165, A61K31/4152, A61K31/4525, A61K31/55, A61K45/06, A61K47/40, A61P25/00, A61P25/22
[2021/15]
CPC:
A61K31/55 (EP,IL,KR,US); A61K31/42 (IL,KR,US); A61K31/135 (EP,IL,KR,US);
A61K31/165 (EP,IL,KR,US); A61K31/405 (IL,KR); A61K31/4152 (EP,IL,US);
A61K31/4525 (EP,IL,US); A61K31/495 (IL,KR); A61K31/496 (IL,KR,US);
A61K31/554 (EP,IL,US); A61K45/06 (EP,IL,US); A61K47/40 (EP,IL,US);
A61K9/0019 (EP,IL,US); A61K9/0053 (IL,US); A61P25/00 (EP,IL,US);
A61P25/22 (EP,IL,KR,US); A61P25/24 (EP,IL,KR,US); A61K2300/00 (IL,KR,US) (-)
C-Set:
A61K31/135, A61K2300/00 (EP,US);
A61K31/165, A61K2300/00 (EP,US);
A61K31/4152, A61K2300/00 (EP,US);
A61K31/4525, A61K2300/00 (US,EP);
A61K31/554, A61K2300/00 (US,EP);
A61K31/55, A61K2300/00 (US,EP)
(-)
Former IPC [2020/15]A61K31/42, A61K31/55, A61K31/135, A61P25/00, A61P25/24
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/15]  
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:FORMULIERUNGEN ZUR BEHANDLUNG VON POSTTRAUMATISCHER BELASTUNGSSTÖRUNG[2020/15]
English:FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER[2020/15]
French:FORMULATIONS POUR LE TRAITEMENT D'UN TROUBLE DE STRESS POST-TRAUMATIQUE[2020/15]
Entry into regional phase23.12.2019National basic fee paid 
23.12.2019Search fee paid 
23.12.2019Designation fee(s) paid 
23.12.2019Examination fee paid 
Examination procedure23.12.2019Examination requested  [2020/15]
07.10.2021Amendment by applicant (claims and/or description)
10.02.2023Despatch of a communication from the examining division (Time limit: M02)
03.04.2023Reply to a communication from the examining division
05.01.2024Communication of intention to grant the patent
29.04.2024Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
29.04.2024Fee for grant paid
29.04.2024Fee for publishing/printing paid
16.05.2024Communication of intention to grant the patent
10.07.2024Receipt of the translation of the claim(s)
Opposition(s)15.05.2025No opposition filed within time limit [2025/30]
Fees paidRenewal fee
22.05.2020Renewal fee patent year 03
18.05.2021Renewal fee patent year 04
23.03.2022Renewal fee patent year 05
30.03.2023Renewal fee patent year 06
29.05.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ14.08.2024
ES14.08.2024
HR14.08.2024
MC14.08.2024
PL14.08.2024
SK14.08.2024
SM14.08.2024
NO14.11.2024
RS14.11.2024
GR15.11.2024
IS14.12.2024
[2026/11]
Former [2025/23]CZ14.08.2024
ES14.08.2024
HR14.08.2024
PL14.08.2024
SK14.08.2024
SM14.08.2024
NO14.11.2024
RS14.11.2024
GR15.11.2024
IS14.12.2024
Former [2025/21]ES14.08.2024
HR14.08.2024
PL14.08.2024
SM14.08.2024
NO14.11.2024
RS14.11.2024
GR15.11.2024
IS14.12.2024
Former [2025/10]ES14.08.2024
HR14.08.2024
PL14.08.2024
NO14.11.2024
RS14.11.2024
GR15.11.2024
IS14.12.2024
Former [2025/09]PL14.08.2024
NO14.11.2024
GR15.11.2024
IS14.12.2024
Former [2025/08]PL14.08.2024
NO14.11.2024
GR15.11.2024
Documents cited:Search[X] WO2005016319  
 [X] WO2016061320  (ROWAN UNIVERSITY et al.) [X] 1,3-5 * claims 1,2,10,12,15 * * page 3, line 15 - line 33 * * page 6, line 23 - line 31 * * page 27 - page 30; example 7 *
International search[XY] US2010216805  (BARLOW CARROLEE et al.) [X] 1-5, 8-14 * para [0002],[0122], [0173],[0179]- [0194], [0264] , claims 1,2, 28 para [0002],[0122],[0159], [0173],[0179]- [0194], [0264] , claims 1,2, 28 *[Y] 1-19
 [Y] US2014018349  (HERESCO-LEVY URIEL et al.) [Y] 6, 7, 15-17 * para [0041]-[0046] *
 [XY] WO2014011590  (JAVITT DANIEL C et al.) [X] 18, 19 * para [007], [0037], [0046], [0054], [0056], [0060]-[0064], [0070], [0075], [0107], [0121], [0125], [0127] para [007], [0037], [0046], [0054], [0056], [0060]-[0064], [0070], [0075], [0107], [0121], [0125], [0127] *[Y] 6, 7, 18, 19
 [XY]   URIEL HERESCO- LEVY ET AL.: "Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder", INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, vol. 5, 10 July 2002 (2002-07-10), pages 301 - 307, XP009169326 [X] 1 * ab stract ab stract * [Y] 1-19

DOI:   http://dx.doi.org/10.1017/S1461145702003061
 [Y]   THOMAS STECKLER ET AL.: "Pharmacological Treatment of PTSD - Established and New Approaches", NEUROPHARMACOLOGY, vol. 62, no. 2, 1 February 2013 (2013-02-01), pages 617 - 627, XP028445222 [Y] 15-17 * page 7 second para *

DOI:   http://dx.doi.org/10.1016/j.neuropharm.2011.06.012
Examination  DIFEDE JOANN ET AL: "D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial", NEUROPSYCHOPHARMACOLOGY, vol. 39, no. 5, 1 April 2014 (2014-04-01), Cham, pages 1052 - 1058, XP093020337, ISSN: 0893-133X, DOI: 10.1038/npp.2013.317

DOI:   http://dx.doi.org/10.1038/npp.2013.317
by applicantWO2005016319
 US2010216805
 US2014018349
 WO2014011590
 WO2016061320
 US7875632
 US7868176
 US7863296
 US7820695
 US7713995
   ALEXANDER: "Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents", P T., vol. 37, no. 1, 2012, pages 32 - 8
   LAITMAN ET AL.: "The alpha1 adrenoceptor antagonist prazosin enhances sleep continuity in fear-conditioned Wistar-Kyoto rats", PROGNEUROPSYCHOPHARMACOLBIOL PSYCHIATRY, vol. 49, 2014, pages 7 - 15
   HERESCO-LEVY ET AL., INTERN.J NEUROPSYCHOPHARMACOLOGY, vol. 5, 2002, pages 301 - 307
   STECKLERRISBROUGH, NEUROPHARMACOLOGY, vol. 62, 2012, pages 617 - 627
   CAS, no. 68-41-7
   ZHU MNIX DEADAM RDCHILDS JMPELOQUIN CA: "Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids", PHARMACOTHERAPY, vol. 21, no. 8, 2001, pages 891 - 7
   PARK SIOH JJANG KYOON JMOON SJPARK JSLEE JHSONG JJANG IJYU KS: "Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers", ANTIMICROB AGENTS CHEMOTHER, vol. 59, no. 8, 2015, pages 4429 - 35
   HUNG WYYU MCCHIANG YCCHANG JHCHIANG CYCHANG CCCHUANG HCBAI KJ: "Serum concentrations of cycloserine and outcome of multi drug-resistant tuberculosis in Northern Taiwan", INT J TUBERC LUNG DIS, vol. 18, no. 5, 2014, pages 601 - 6
   BESAG FM, EXPERT OPIN DRUG SAF, vol. 3, 2004, pages 1 - 8
   CARLSSON ET AL., J NEURAL TRANSM, vol. 95, 1994, pages 223 - 233
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.